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Summary
Background Idiopathic and heritable pulmonary arterial hypertension form a rare but molecularly heterogeneous 
disease group. We aimed to measure and validate differences in plasma concentrations of proteins that are associated 
with survival in patients with idiopathic or heritable pulmonary arterial hypertension to improve risk stratification.
Methods In this observational cohort study, we enrolled patients with idiopathic or heritable pulmonary arterial 
hypertension from London (UK; cohorts 1 and 2), Giessen (Germany; cohort 3), and Paris (France; cohort 4). 
Blood samples were collected at routine clinical appointment visits, clinical data were collected within 30 days of 
blood sampling, and biochemical data were collected within 7 days of blood sampling. We used an aptamer-based 
assay of 1129 plasma proteins, and patient clinical details were concealed to the technicians. We identified a panel of 
prognostic proteins, confirmed with alternative targeted assays, which we evaluated against the established prognostic 
risk equation for pulmonary arterial hypertension derived from the REVEAL registry. All-cause mortality was the 
primary endpoint.
Findings 20 proteins differentiated survivors and non-survivors in 143 consecutive patients with idiopathic or 
heritable pulmonary arterial hypertension with 2 years’ follow-up (cohort 1) and in a further 75 patients with 
2·5 years’ follow-up (cohort 2). Nine proteins were both prognostic independent of plasma NT-proBNP concentrations 
and confirmed by targeted assays. The functions of these proteins relate to myocardial stress, inflammation, 
pulmonary vascular cellular dysfunction and structural dysregulation, iron status, and coagulation. A cutoff-based 
score using the panel of nine proteins provided prognostic information independent of the REVEAL equation, 
improving the C statistic from area under the curve 0·83 (for REVEAL risk score, 95% CI 0·77–0·89; p<0·0001) to 
0·91 (for panel and REVEAL 0·87–0·96; p<0·0001) and improving reclassification indices without detriment to 
calibration. Poor survival was preceded by an adverse change in panel score in paired samples from 43 incident 
patients with pulmonary arterial hypertension in cohort 3 (p=0·0133). The protein panel was validated in 93 patients 
with idiopathic or heritable pulmonary arterial hypertension in cohort 4, with 4·4 years’ follow-up and improved risk 
estimates, providing complementary information to the clinical risk equation.
Interpretation A combination of nine circulating proteins identifies patients with pulmonary arterial hypertension 
with a high risk of mortality, independent of existing clinical assessments, and might have a use in clinical 
management and the evaluation of new therapies.
Funding National Institute for Health Research, Wellcome Trust, British Heart Foundation, Assistance Publique-Hôpitaux 
de Paris, Inserm, Université Paris-Sud, and Agence Nationale de la Recherche.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence. 
Introduction
Idiopathic and heritable pulmonary arterial hypertension 
constitute a rare disease group characterised by an 
imbalance in endothelial-derived vasoactive factors, 
inflam mation, and structural remodelling of pulmonary 
vessels.1 The resultant pressure load on the right 
ventricle causes premature death from heart failure.1,2 
The incidence of pulmonary arterial hypertension is 
estimated at 1–7·6 per million per year and cases of 
idio pathic or heritable pulmonary arterial hypertension 
account for 0·9–2·6 per million per year.3 Estimated 
3-year survival is 58–74%,2,4 but the disease is hetero-
geneous; several biological mech anisms1 and a range 
of variants in several genes5 have been linked to 
patho genesis, and life expectancy is variable. Regular 
assess ment of disease severity and prognosis is 
necessary to guide clinical management. The existing 
guidelines recommend a combination of established 
prognostic parameters on the basis of clinical assess-
ment, imaging, and biochemistry.6 These clinical 
parameters are not always available for each patient visit 
and existing risk assessments have poor accuracy (with 
C statistics ranging between 0·57 for the US National 
Institutes of Health,7 0·59 for the French Registries,2 and 
0·77 for the REVEAL equation8), leaving considerable 
scope for improve ment.3
Lancet Respir Med 2017
Published Online 
June 14, 2017 
http://dx.doi.org/10.1016/
S2213-2600(17)30161-3
See Online/Comment 
http://dx.doi.org/10.1016/
S2213-2600(17)30209-6
Department of Medicine 
(C J Rhodes PhD, J Wharton PhD, 
P Ghataorhe MD, G Watson MD, 
Prof M R Wilkins MD) and 
National Heart and Lung 
Institute, Imperial College 
London, Hammersmith 
Campus, London, UK 
(L S Howard DPhil, 
J S R Gibbs MD); National 
Pulmonary Hypertension 
Service, Imperial College 
Healthcare NHS Trust, 
Hammersmith Hospital, 
London, UK (L S Howard, 
J S R Gibbs); Department of 
Infection, Immunity and 
Cardiovascular Disease, 
University of Sheffield, 
Sheffield, UK (A Lawrie PhD); 
Sheffield Pulmonary Vascular 
Disease Unit, Royal Hallamshire 
Hospital, Sheffield, UK 
(R Condliffe MD, C A Elliot MD, 
Prof D G Kiely MD); University 
Paris-Sud, Université 
Paris-Saclay, Le Kremlin-Bicêtre, 
Paris, France (B Girerd PhD, 
Prof G Simonneau MD, 
Prof D Montani MD, 
Prof O Sitbon MD, 
Prof M Humbert MD); AP-HP, 
Service de Pneumologie, Hôpital 
Bicêtre, Le Kremlin-Bicêtre, 
Paris, France (B Girerd, 
Prof G Simonneau, 
Prof D Montani, Prof O Sitbon, 
Prof M Humbert); Inserm UMR_S 
999, Hôpital Marie 
Lannelongue, 
Le Plessis-Robinson, Paris, 
France (B Girerd, 
Prof G Simonneau, 
Prof D Montani, Prof O Sitbon, 
Prof M Humbert); and University 
of Giessen and Marburg Lung 
Center, Member of the German 
Center for Lung Research (DZL), 
Giessen, Germany (H Gall MD, 
Prof R T Schermuly PhD, 
Prof H A Ghofrani MD)
Articles
2 www.thelancet.com/respiratory   Published online June 14, 2017   http://dx.doi.org/10.1016/S2213-2600(17)30161-3
Correspondence to: 
Prof Martin R Wilkins, 
Department of Medicine, 
Imperial College London, 
Hammersmith Campus, London 
W12 0NN, UK 
m.wilkins@imperial.ac.uk
The existing management guidelines include the 
measurement of plasma brain natriuretic peptide (BNP) 
or N-terminal proBNP (NT-proBNP) concentrations, an 
indicator of right ventricular function, in the assessment 
of patients with pulmonary arterial hypertension.6 
Biomarkers reporting other components of the patho-
physiology of idiopathic pulmonary arterial hypertension, 
such as inflammation (interleukin 6 and growth 
differentiation factor 15), renal function (creatinine), and 
iron status (red cell distribution width), also predict 
clinical outcome,9–12 but none are used routinely. The use 
of multiple biomarkers could improve risk assessment.
Proteomics offers an unbiased approach to identifying 
and quantifying multiple biomarkers representative of 
disease processes. Mass spectrometry-based proteomic 
analysis of lung tissue, plasma, and cultured cells from 
patients with pulmonary arterial hypertension has 
identified a small number of dysregulated proteins.13–15 
Alternative high-throughput strategies exploiting 
targeted peptide-binding reagents in a multiplex manner 
permit the screening of large numbers of identifiable 
proteins. One such technology uses DNA-based aptamer 
reagents, known as SOMAmers, that are modified to 
improve binding kinetics.16,17
We used a SomaScan array to measure concentrations 
of 1129 proteins in plasma to identify and validate 
circulating proteomic signatures that predict survival of 
patients with idiopathic or heritable pulmonary arterial 
hypertension.
Methods
Study design and participants
In this multicentre, observational cohort study, we 
identified and analysed four cohorts of patients with 
idiopathic or heritable pulmonary arterial hypertension 
from three expert centres recognised internationally as 
centres of excellence for pulmonary arterial hypertension 
diagnosis and management in London (UK; cohorts 1 
and 2), Giessen (Germany; cohort 3), and Paris (France; 
cohort 4). The diagnostic criteria for idiopathic or 
heritable pul monary arterial hypertension over the 
course of this study were stable: raised mean pulmonary 
artery pressure of more than 25 mm Hg, with pulmonary 
capillary wedge pressure less than 15 mm Hg (and 
pulmonary vascular resistance [PVR] >3 Wood units) at 
rest with exclusion of known associated diseases. The 
guidelines quoted are internationally agreed. Samples 
from 25 healthy controls were also collected at 
Hammersmith Hospital for comparison of proteomic 
and alternative assay measurements.6 All samples and 
data were obtained with informed consent and local 
research ethics committee approval.
Procedures
Patients were not fasting and were sampled at their routine 
clinical appointment visits (397 in total for all patients). 
Peripheral venous blood samples were collected using 
EDTA (edetic acid) for cohorts 1, 2, and 3 or sodium citrate 
Vacutainer tubes (BD Biosciences, Oxford, UK) for 
Research in context
Evidence before this study
We searched PubMed for relevant articles (before March 1, 2017) 
with search terms including “pulmonary arterial hypertension”, 
“prognostic”, “proteomics”, and “biomarker”. Several studies 
report single biomarkers for pulmonary arterial hypertension, 
usually derived from other diseases, but none have undertaken 
unbiased screening of large numbers of plasma markers and 
related these to outcomes in pulmonary arterial hypertension. 
The prognostication of pulmonary arterial hypertension remains 
poor. Pulmonary arterial hypertension is diagnosed at cardiac 
catheterisation. Thereafter a combination of exercise capacity 
(eg, 6-min walk test), patient-reported symptoms (eg, functional 
class assessment), echocardiography, and circulating NT-proBNP 
concentrations—captured in prognostic equations such as the 
REVEAL score—are used to follow disease progression, response 
to treatment, and make clinical management decisions. Not all 
these measurements are made at each visit and some (eg, 6-min 
walk test) are subject to confounding factors. Better, non- 
invasive, and objective methods of assessment are needed that 
can be deployed in the clinical setting.
Added value of this study
We did an unbiased screen of 1129 proteins measured in 
plasma samples collected on routine clinic visits. 
Measurement of circulating concentrations of nine proteins in 
combination predicted survival, which outperformed 
traditional clinical assessments. A prognostic score on the 
basis of plasma concentrations of the nine proteins was 
validated in independent cohorts from three countries 
(UK, France, and Germany) and is relevant to both incident 
and prevalent cases of pulmonary arterial hypertension. 
An increase in the panel score over time is associated with 
increased mortality.
Implications of all the available evidence
The guidelines for prognostication in pulmonary arterial 
hypertension recommend the use of only one blood 
biomarker, BNP or NT-proBNP, and consideration of a 
multitude of clinical measures, which when formalised into 
risk equations perform only moderately well in predicting 
outcomes. These data suggest that a panel of nine proteins, 
which report on different pathogenic mechanisms linked to 
pulmonary arterial hypertension, can be used to stratify 
patients according to risk and assess response to treatment 
better than existing clinical tools. Further investigation of the 
pathways represented in the protein panel might also offer 
new insights for the development of novel therapies.
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cohort 4, immediately put on ice, centrifuged (1300 × g, 
15 min) within 30 min of collection, and plasma aliquots 
were stored at –80°C until required. The plasma samples 
underwent one freeze–thaw cycle to aliquot 120 µL for the 
SomaScan assay and provide other aliquots for NT-proBNP 
and targeted assays. Clinical data were collected within 
30 days of blood sampling and biochemical data were 
collected within 7 days of blood sampling.11 We calculated 
the REVEAL prognostic equation,8 and fitted it to the study 
cohorts. The equation includes categories on the basis 
of sub-diagnosis, age, sex, renal insufficiency, WHO 
functional class, systolic blood pressure, heart rate, 6-min 
Cohort 1 (n=143) Cohort 2 (n=75) Cohort 3 (n=43) Cohort 4 (n=93)
Recruitment period 2011–13 2002–11 2004–11 2003–11
Age, years 53 (41–69) 55 (39–70) 50 (29–61) 54 (39–66)
Sex
Females 100 (70%) 45 (60%) 28 (65%) 58 (62%)
Males 43 (30%) 30 (40%) 15 (35%) 35 (38%)
Ethnic origin
White 117 (82%) 59 (79%) 43 (100%) 78 (84%)
Asian 14 (10%) 11 (15%) 0 5 (5%)
Black 4 (3%) 3 (4%) 0 8 (9%)
Other ethnicity or not stated 8 (6%) 2 (3%) 0 2 (2%)
Idiopathic pulmonary arterial hypertension 140 (98%) 71 (95%) 43 (100%) 77 (83%)
Heritable pulmonary arterial hypertension 3 (2%) 4 (5%) 0 16 (17%)
WHO FC
Class I 6 (4%) 1 (1%) 0 4 (4%)
Class II 32 (22%) 14 (19%) 6 (14%) 28 (30%)
Class III 91 (64%) 41 (55%) 28 (65%) 55 (59%)
Class IV 14 (10%) 19 (25%) 9 (21%) 6 (6%)
6-min walk, m 339 (144–432) 258 (120–369) 359 (251–425) 390 (300–433)
mPAP, mm Hg 52 (43–62) 51 (46–62) 50 (45–58) 51 (44–61)
mRAP, mm Hg 10 (6–13) 12 (8–17·5) 7 (3–10) 6 (3·5–10)
PAWP, mm Hg 10 (8–14) 10 (7–13) 8 (5–9) 8 (6–10)
CI, L/min/kg/m² 2·13 (1·71–2·65) 2·2 (1·71–2·59) 2·23 (1·89–2·60) 2·54 (2·06–3·40)
CO, L/min 4·16 (3·18–5·39) 4·13 (3·00–5·20) 3·80 (3·23–4·41) 4·30 (3·47–5·50)
PVR, Wood units 10·0 (6·0–14·5) 9·3 (7·5–13·1) 11·4 (8·4–15·0) 9·9 (6·4–14·3)
Treatment naive 13 (9%) 19 (25%) 43 (100%) 24 (26%)
Monotherapy
CCB 5 (3%) 0 0 1 (1%)
PDE5 32 (22%) 14 (19%) 0 7 (8%)
ERA 14 (10%) 16 (21%) 0 26 (28%)
Prost 1 (1%) 4 (5%) 0 2 (2%)
Dual therapy
ERA and PDE5 53 (37%) 10 (13%) 0 21 (23%)
Prost and ERA 2 (1%) 5 (7%) 0 2 (2%)
Prost and PDE5 7 (5%) 5 (7%) 0 3 (3%)
Triple therapy 16 (11%) 2 (3%) 0 7 (8%)
Estimated survival
1-year follow-up 96% 89% 98% 91%
2-year follow-up 88% 63% 88% 88%
3-year follow-up 0 45% 86% 77%
Time after diagnosis sampled, years 3·16 (0·54–7·3) 1·11 (0·37–2·45) 0·41 (0·32–0·89)* 0·88 (0·15–1·82)
Follow-up, years 2·0 (1·6–2·2) 2·5 (1·5–4·9) 6·5 (4·3–9·9) 4·4 (3·0–5·7)
Data are median (IQR), n (%), or n. WHO FC=WHO/New York Heart Association Functional Classification. Shuttle walk=incremental shuttle walk test. mPAP=mean pulmonary 
artery pressure. mRAP=mean right atrial pressure. PAWP=pulmonary artery wedge pressure. CI=cardiac index. CO=cardiac output. PVR=pulmonary vascular resistance. 
CCB=calcium channel blocker. ERA=endothelin receptor antagonist. PDE5=phosphodiesterase 5 inhibitors. Prost=prostanoid analogues. IQR=interquartile range. *Years after 
diagnosis sampled for second sample shown; baseline samples were taken at diagnosis.
Table 1: Baseline characteristics
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walk distance, NT-proBNP, presence of pericardial 
effusion, percentage predicted diffusing capacity for 
carbon monoxide, mean right atrial pressure, and PVR. 
Proteomic analysis was done with SOMAscanV3 
(Somalogic Inc, Boulder, CO, USA)16 and patient status 
was concealed to the technicians. The list of 1129 targeted 
proteins has been reported previously.17 To minimise 
between-experiment variation, bridging samples were 
included in all experiments; specifically, to check 
consistency of the measurements we included samples 
from 24 patients from cohort 1 in all experiments to verify 
that the measurements from experiment to experiment 
were comparable. Median variation in relative fluorescence 
units between experiments was less than 10%, and more 
than 90% of analytes showed less than 20% variation in 
average levels between experiments. Following selection of 
the proteins of interest from analyses of cohort 1 samples, 
we measured the same proteins again in the same samples 
used in the proteomic analysis by alternative commercially 
available assays, each specific for the protein of interest, to 
check that the two methods agreed; the ELISA and 
Luminex assays used to validate the SOMAscan 
measurements are detailed in the appendix (p 3).
Outcomes
All-cause mortality was the primary endpoint. In a 
secondary analysis, lung transplantation or death was 
used as a composite endpoint.
Statistical analysis
We present differences in protein concentrations by 
subtraction of log relative fluorescence units. We 
assessed the association between patient characteristics 
and biomarkers by Spearman’s rank test or 
Mann–Whitney U test and Kruskal–Wallis test for 
categorical variables.
We did survival analyses using time from sampling 
to death or censoring. We compared the protein 
concentrations of survivors and non-survivors (overall 
survival in cohort 1 and at 2·5 years’ follow-up in 
cohort 2) with Mann–Whitney tests to maximise the 
power of the protein validation analysis. We used 
random sample analysis to assess robustness of 
differences between survivors and non-survivors: we 
repeated Mann–Whitney analyses 18 times in both 
discovery and validation (cohorts 1 and 2), each time 
removing one patient out of six patients in 
three randomised blocks, with each sample left out of 
three analyses.
We tested two panel scoring systems. One system was 
based on a simple count of proteins indicating risk on the 
basis of receiver operating characteristic (ROC) cutoffs, 
and the second was a Cox regression model, in which 
predicted hazard based on continuous biomarker 
concentrations was calculated on the basis of fitting to 
the discovery cohort.
For assessment of discrimination, we used ROC curves 
to compare prognostic discriminatory power of bio-
markers. Kaplan–Meier plots illustrated events (deaths) 
in relation to biomarker levels and predicted risk in Cox 
models, assessed by the log-rank test. We fitted the 
simple panel score and REVEAL equation (an accepted 
clinical score derived from a variety of clinical 
parameters)8 to Cox models to test the additional value 
and potential clinical use of the panel. For reclassification, 
we calculated indices—net reclassification index (NRI) 
and the relative integrated discrimination improve ment 
(IDI) statistic18—with R package PredictABEL19 for the 
addition of the prognostic panel score to the REVEAL 
equation.8 We developed the models in cohorts 1 and 2 
combined and validated them in cohort 4. Cohort 3 was 
used to test the performance of the proteins and panel 
score longitudinally, before and after initiation of targeted 
therapy. We assessed calibration of the Cox models by 
comparing predicted mortality of patients against 
observed mortality using Harrell’s rms package in R. We 
converted variables to Z-scores (SD around mean) before 
testing by Cox regression. We did calculations with SPSS 
version 21.0 and R version 3.0.2.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had the final 
responsibility for the decision to submit for publication.
Figure 1: Study design
Protein discovery (cohort 1)
143 consecutive patients with pulmonary arterial hypertension enrolled 
134 of 1129 proteins identify non-survivors
40 of 134 proteins identify non-survivors 
20 proteins prioritised by random sampling analysis
14 proteins independent of established prognostic biomarker NT-proBNP
Protein validation (cohort 2)
75 patients with pulmonary arterial hypertension enrolled
Nine-protein panel score
Counts number of proteins meeting optimal survival cutoffs in each patient
Panel validation (cohort 4)
93 patients with pulmonary arterial
hypertension enrolled
Serial samples (cohort 3)
43 patients with pulmonary arterial
hypertension enrolled
Confirmation by alternative assays (ELISAs and Luminex)
All 14 proteins tested, nine proteins validated 
See Online for appendix
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Results
Cohorts 1 and 2 were censored on May 15, 2014, cohort 3 
on May 21, 2015, and cohort 4 on June 1, 2014. We 
assessed patients for eligibility between Oct 25, 2011, 
and Aug 13, 2013, for cohort 1, between Oct 24, 2002, and 
June 22, 2011, for cohort 2, between Aug 27, 2003, 
and Nov 19, 2012, for cohort 3, and between June 2, 2003, 
and Dec 23, 2011, for cohort 4 (table 1, figure 1). At the 
end of the follow-up periods, 18 patients died in cohort 1, 
37 patients died in cohort 2, 17 patients died in cohort 3, 
and 39 patients died in cohort 4; no patients were lost to 
follow-up. Nine patients (n=3 cohort 1 and n=6 cohort 2) 
underwent lung or heart and lung transplantation; seven 
of nine patients who had undergone transplantation 
died during follow-up.
Concentrations of 134 proteins were associated with 
overall survival in cohort 1 (figure 2A). 40 of these 
proteins were validated as able to differentiate between 
survivors and non-survivors in cohort 2. 20 prognostic 
proteins, including BNP, were prioritised by random 
sampling analysis as the most robust (appendix p 4). 
These proteins had good specificity and sensitivity in 
ROC analysis (figure 2B and appendix p 5), and protein 
concentrations that distinguished between survivors and 
non-survivors in cohort 1 and performed well in cohort 2 
were identified (figure 2C). To ensure the small number 
of patients with heritable pulmonary arterial hypertension 
were not confounding, we did an analysis excluding 
these seven patients and found that the 20 proteins were 
again significant in both discovery (cohort 1) and 
validation (cohort 2) analyses (appendix p 6).
We investigated whether the 20 prognostic proteins 
offered an improvement in risk estimation in addition 
to the only prognostic protein biomarker currently in 
use in pulmonary arterial hypertension, namely 
NT-proBNP. 14 of 20 proteins were each prognostic 
independent of NT-proBNP in Cox models with death 
as the primary endpoint (all p<0·05; figure 2D). With 
transplantation or death as a composite endpoint, all 
14 proteins remained significant and independent of 
NT-proBNP (data not shown). ASAH2Factor H
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Figure 2: Prognostic protein panel analysis
(A) Volcano plot illustrating differences in protein expression between survivors 
and non-survivors. (B) ROC analysis of 20 selected proteins showing sensitivity 
and 1 – specificity at cutoffs. (C) Kaplan–Meier survival analysis of patients with 
idiopathic pulmonary arterial hypertension in cohort 2 divided by TIMP-2 cutoff 
derived from ROC analysis of cohort 1. (D) Hazard ratios and 95% CI from Cox 
regression analysis comparing 20 prognostic proteins with established prognostic 
marker, NT-proBNP. (E) Commercially available ELISA or Luminex assays targeting 
the 14 independently prognostic proteins used to validate SomaScan 
measurements in a subset of 80 plasma samples selected from cohort 1 (n=55) 
and healthy controls (n=25), with samples with high and low concentrations of 
the analytes chosen. Nine proteins were validated and further studied in cohort 3 
(serial samples) and cohort 4 (validation cohort). This scatter-plot illustrates 
TIMP-1 measurements by SomaScan and Luminex assays in idiopathic pulmonary 
arterial hypertension cohort 4. Cutoffs for SomaScan and Luminex values derived 
by percentile equalling ROC-derived cutoff in cohort 1 are indicated by dashed 
lines. Statistics indicate Spearman’s rank correlation. ROC=receiver operating 
characteristic. RFU=relative fluorescence unit.
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A significant correlation between values in the SomaScan 
and the independent ELISA or Luminex assay was shown 
for nine protein measure ments (all p<0·05, Spearman’s 
rank [data not shown])—interleukin-1 receptor-like 1 
(IL1R1/ST2), tissue inhibitors of metallo proteinases 
(TIMP-1 and TIMP-2), plasminogen, apolipoprotein-E 
(ApoE), erythropoietin (EPO), complement factor H and 
factor D, and insulin-like growth factor binding protein-1 
(IGFBP-1). The measurements for these nine proteins 
allowed us to derive threshold protein concentrations 
associated with survival (figure 2E, appendix p 7), and we 
derived threshold concentrations for each protein in 
cohort 1 and validated these in cohort 2.
We used the prognostic thresholds for each of these 
nine proteins to produce a protein panel score for each 
patient, whereby each protein indicating risk (ie, when 
the plasma concentration was above or below the 
threshold cutoff for survival) added 1 to a patient’s score. 
This calculation produced scores ranging from 0 to 9 for 
each patient and discriminated non-survivors in discovery 
(for cohort 1, area under the curve [AUC] 0·93, 95% CI 
0·88–0·99) and validation (for cohort 2, 0·86, 0·77–0·94). 
The simplified scoring of each protein based on a cutoff 
performed as well as an equation using continuous 
protein concentrations, which was also derived in 
cohort 1 and tested in cohort 2 (AUC 0·83, 95% CI 
0·75–0·92; appendix p 9). Increasing panel scores clearly 
distinguished risk groups (figure 3A, appendix p 10).
Removal of any two proteins did not impair the per-
formance of the remaining panel, suggesting no protein 
was dominant, and emphasising the dis criminating 
power of the combination (appendix p 11). The panel 
score was also prognostic in a sub-analysis of samples 
obtained before initiation of therapy, comprising 
77 (35%) of 218 patients from cohorts 1 and 2 
(appendix p 12) and in groups of patients from cohorts 1 
Figure 3: Survival analysis of panel score and established prognostic factors
Kaplan–Meier survival estimates in patients with different panel scores, in all patients with idiopathic pulmonary arterial hypertension from (A) cohorts 1 and 2 and 
(B) cohort 4. ROC analysis of Cox models before and after addition of the prognostic protein panel to the established equation, in all patients with idiopathic 
pulmonary arterial hypertension from (C) cohorts 1 and 2 and (D) cohort 4. ROC=receiver operating characteristic. AUC=area under the curve.
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and 2 stratified by age (above and below 50 years; 
appendix p 13) and bilirubin concentration (21 µmol/L, 
the upper limit of the normal range in the clinical assay; 
appendix p 13).
43 patients were sampled at diagnosis and after 
initiating therapy in cohort 3 (median time between 
samples 4 months, IQR 3–10). Although changes in the 
concentrations of any individual protein, including 
NT-proBNP, were not associated with outcome, an 
increasing panel score was prognostic (p=0·0186; 
figure 4A). Patients whose protein panel score was higher 
at follow-up than at baseline showed poorer survival than 
those whose scores remained stable or improved 
(p=0·0133; figure 4B), which identified patients who had 
not responded to therapy. These patients had similar 
clinical characteristics at baseline (appendix p 8). Changes 
in the panel score appear more sensitive than other 
measures—eg, the small changes in pulmonary vascular 
resistance recorded at repeat catheterisation were not 
associated with survival (appendix p 14).
The protein panel score was further validated in an 
independent group of 93 patients with idiopathic or 
heritable pulmonary arterial hypertension from cohort 4 
(4·4 years’ [IQR 3·0–5·7] follow-up; table 1); an increasing 
panel score distinguished risk groups (figure 3B, 
appendix p 10). In panel development (cohorts 1 and 2) 
and panel validation analyses (in cohort 4), the panel 
score predicted survival independent of NT-proBNP 
measure ments (appendix p 8).
Results from Cox models confirmed that the REVEAL 
equation was prognostic and that the protein panel score 
provided independent prognostic information in both 
panel development and panel validation (table 2). The 
categorical NRI indicated that the protein panel score 
reclassified more patients who died during follow-up at 
above-average risk and vice versa, while the relative IDI 
showed a 50–223% relative improve ment after addition 
of the panel score to the model. This outcome means that 
the protein panel is changing the risk estimates for 
patients in a significant proportion of individuals, and is 
providing prognostic information additional to the 
established equation. In both the panel development and 
REVEAL equation Panel of nine proteins
Performance of equation and panel in combined model
C statistic
Development 0·83 (0·77–0·89) 0·89 (0·84–0·94)
Validation 0·72 (0·59–0·84) 0·83 (0·72–0·94)
Hazard ratio in model
Development 1·73 (1·36–2·21) 2·44 (1·79–3·33)
Validation 1·42 (1·01–1·99) 1·9 (1·33–2·72)
Effect on performance of adding panel to equation
Categorical NRI (above/below overall event rate)
Development Reference 0·20 (0·09–0·31)
Validation Reference 0·39 (0·07–0·70)
IDI
Development Reference 0·17 (0·09–0·24)
Validation Reference 0·13 (0·06–0·20)
Relative IDI
Development Reference 0·50 (0·28–0·72)
Validation Reference 2·23 (1·05–3·41)
Δ C statistic
Development Reference 0·083 (0·052–0·114)
Validation Reference 0·095 (0·026–0·164)
Hazard ratios from Cox regression analyses of panel score and REVEAL equation, 
categorical NRI based on overall death—25% (55 deaths in 218 patients) at 
2·5 years in development analyses (cohorts 1 and 2) and 23% (21 deaths in 
93 patients) at 3 years in validation analyses (cohort 3)—relative IDI 
(IDI/discrimination slope), and improvement in C statistic (Δ C statistic) after 
addition of the panel to the REVEAL equation. Model development was performed 
in cohorts 1 and 2 combined, and validation in cohort 4. NRI=net reclassification 
index. IDI=integrated discrimination improvement.
Table 2: Model performance
Figure 4: Prognostic value of changes in the protein panel score from 
diagnosis to after initiation of therapy
(A) Cox proportional hazard estimates associated with changes in individual 
proteins and the overall panel score, showing only the combination of proteins 
into the score is significantly associated with outcomes. (B) Kaplan–Meier 
survival estimates in patients with serial panel score measurements (cohort 3), 
showing an increase in the panel score from diagnosis to after initiation of 
therapy is associated with poor outcomes.
A
B
0·25 0·5 1 2 4
Hazard ratio of change between samples
Panel score
IL-1 R4
Epo
Factor D
IGFBP-1
TIMP-2
TIMP-1
Factor H
Plasminogen
Apo E
Panel score
No increase
Increase
0 2 4 6 8 10
28
15
26
11
21
8
15
4
8
3
3
0
Years survived since sampled
p=0·0133
0
0·2
0·4
0·6
0·8
1·0
Cu
m
ul
at
iv
e 
su
rv
iv
al
Higher
prognostic
protein
concentrations
Lower
prognostic
protein
concentrations
Change in panel score
 No increase
 Increase
Articles
8 www.thelancet.com/respiratory   Published online June 14, 2017   http://dx.doi.org/10.1016/S2213-2600(17)30161-3
panel validation analyses, the protein panel score 
improved the C statistic by a similar margin (0·08–0·09; 
for REVEAL risk score AUC 0·83, 95% CI 0·77–0·89; 
p<0·0001; for panel and REVEAL 0·91, 0·87–0·96; 
p<0·0001; figure 3C, D, table 2). Calibration in both 
model development and validation was similar before 
and after addition of the panel score (appendix p 15). 
A combination of the panel score and NT-proBNP as a 
continuous variable performed very similarly to the 
combination of the panel score and REVEAL equation in 
both analyses (appendix p 16).
Discussion
To our knowledge, this study is the first to apply high-
throughput analysis of the plasma proteome to patients 
with idiopathic or heritable pulmonary arterial hyper-
tension. The importance of robust statistical interrogation 
of novel biomarkers versus established criteria in risk 
prediction models has been emphasised before.20 We 
applied these methods extensively and identified nine 
proteins that predict survival independent of the 
established circulating prognostic factor, NT-proBNP. 
A panel score on the basis of plasma concentrations of 
these nine proteins, whereby a score increasing from 0 to 9 
was associated with increased risk in an individual, 
improved clinical risk prediction based on NT-proBNP and 
the REVEAL prognostic equation.8 The protein panel was 
informative when used in incident or prevalent patients, 
and changes in the panel score after initiating therapy had 
clinical use by the identification of patients who had not 
responded to treatment. The protein panel improved 
model discrimination and reclassification without skewing 
calibration, and was validated in an independent cohort of 
patients from a separate expert centre, again in dependent 
of established clinical measurements. 
BNP was one of the initial 20 prognostic proteins 
identified following discovery (cohort 1), validation 
(cohort 2), and random sampling analysis (cohorts 1 
and 2), which gave us confidence in our approach. In the 
final analyses, a panel of nine proteins provided 
information independent of the most up-to-date risk 
equation incorporating many clinical variables. The 
protein components of this panel report on different 
pathways recognised in the pathophysiology of pul monary 
arterial hypertension and collectively are more informative 
than when used individually. ST2, secreted in response to 
stretching myocardiocytes,21 is a potential biomarker in 
chronic heart failure,22 and circulating concentrations can 
also reflect inflammation.23 Increased TIMP expression 
and imbalance in matrix metalloproteinase activity is 
implicated in pulmonary vascular remodelling and 
disease progression in patients with pulmonary arterial 
hypertension.24 Pulmonary ApoE expression is reduced in 
patients with idiopathic pulmonary arterial hypertension,25 
and in experimental models ApoE inhibits the 
proliferation of pulmonary artery smooth muscle cells 
and protects against the development of pulmonary 
arterial hyper tension.26 The IGF-1 system is known to 
have a role in vascular pathologies, such as pulmonary 
arterial hypertension, and IGFBP-1 is one of a family of 
proteins modulating the effects of IGF-1 on vascular 
smooth muscle and endothelial cells.27 Increased 
complement factor D expression and loss of the inhibitory 
factor H predicts dysregulation of the complement system 
and overactivation of inflammation and innate immunity.28 
Finally, increased EPO and reduced plasminogen 
concentrations might reflect the abnormal iron status29 
and prothrombotic state30 of patients with idiopathic 
pulmonary arterial hypertension. The proteins identified 
in this study appear to have biological relevance to 
pulmonary arterial hypertension. None of the proteins 
identified in this study were the same as those identified, 
using the same platform, to predict cardiovascular risk in 
patients with stable coronary heart disease.17
Effective clinical management of patients with idiopathic 
or heritable pulmonary arterial hypertension requires the 
early recognition of patients who are failing to respond to 
treatment and need alternative or additional targeted 
therapies. The existing assessment of patients is dependent 
on subjective reporting of wellbeing to assign functional 
class, functional tests such as the 6-min walk test, which 
lacks specificity, and the availability of data from 
echocardiography.6 The nine-protein panel provides an 
objective measure that improves the prognostic accuracy 
of clinical evaluation.8 Biomarkers should always be used 
in clinical context, but it is relevant that the single addition 
of plasma NT-BNP concentration (a component of the 
REVEAL equation) as a continuous variable to the panel 
score performs as well as the panel score plus the REVEAL 
equation. This observation presents the possibility that the 
use of the protein panel with NT-BNP might provide a 
useful point-of-care test for the assessment and early 
referral of patients with idiopathic or heritable pulmonary 
arterial hypertension for specialist intervention.
This study represents a comprehensive analysis of the 
circulating proteome in patients with idiopathic or 
heritable pulmonary arterial hypertension, leading to the 
discovery of a panel of proteins capable of predicting 
mortality more accurately than established measure-
ments. Although the number of proteins assayed 
represents a broad range of proteins with disparate 
functions, the proteins studied are limited by the 
aptamers developed for the assay. Pulmonary arterial 
hypertension is a rare disease, and the numbers of 
patients in this study preclude the analysis of interactions 
between proteins that might improve prognostication. 
The importance of changes in protein concentrations 
over time and in response to various therapeutic strategies 
requires further pro spective study, with assessments of 
the effect of interval between samples. The heterogeneity 
of pulmonary arterial hypertension and of the patients 
studied in these cohorts (eg, in terms of age, gender, 
disease severity, and genetic background) means that the 
proteins and biological pathways identified in this study 
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might not always be the most important in each individual 
with pulmonary arterial hypertension. We did the 
analyses on independent cohorts of patients recruited at 
three distinct international centres of expertise. The 
differences in occurrence of death were primarily because 
of different durations of follow-up and preclusion of 
long-term survivors in cohort 1 (2011–13) from cohort 2 
(2002–11). The effect of different therapies on the 
concentration of the proteins was not studied and would 
require sampling of the same subjects before and after 
initiation of specific therapies at set timepoints. Fasting 
and dietary status and the method of blood sampling are 
known to affect proteomic measurements, but we did not 
study this here. We validated proteomic measurements 
with alternative experimental methods and similar 
results were observed in both EDTA-preserved and 
sodium citrate-preserved plasma. Blood samples were 
collected alongside routine clinical plasma samples, 
showing the practical deployment of this protein panel in 
a clinical setting. The cost of these blood protein 
measurements would be relatively low compared with 
more complex clinical procedures. The development of a 
dedicated assay to measure all nine proteins together 
would simplify its clinical use.
The prognostic nine-protein panel score powerfully 
selects subgroups of patients that are likely to have events 
(death or transplantation), which could be beneficial for 
targeting aggressive therapeutic strategies or maximising 
the power of clinical trials. The proteins identified warrant 
mechanistic evaluation in addition to examination in 
other distinct disease groups, including other forms of 
pulmonary hypertension and cardiovascular disease.
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